Antibody-enhanced COVID-19 vaccination
- Funded by Academy of Finland
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19Start & end year
20202022Known Financial Commitments (USD)
$627,593.62Funder
Academy of FinlandPrincipal Investigator
Marko SalmiResearch Location
FinlandLead Research Institution
University of TurkuResearch Priority Alignment
N/A
Research Category
Vaccines research, development and implementation
Research Subcategory
Vaccine design and administration
Special Interest Tags
N/A
Study Type
Unspecified
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Adults (18 and older)Older adults (65 and older)
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
A major challenge in COVID-19 vaccinations is to induce robust and good-quality protective immunity, especially in older persons. We will use a clinically approved therapeutic antibodies to overcome these limitations in experimental models. By co-injecting small quantities of immunomodulatory antibodies with the with a vaccine antigen we will revive the COVID-19 vaccine responses in aged immune system, and re-direct the anti-vaccine immune response to the most beneficial protecting direction. Our conceptually new way of using accepted therapeutic antibodies as COVID-19 vaccine adjuvants has the potential to generate more effective vaccine responses with less adverse effects, substantial vaccine-sparing and the protection of older individuals.